Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases

Journal of Hepatology

Volumn 67, Issue 1, 2017, Pages 56-64

  Yamashita, Suguru ^a   Shindoh, Junichi ^a,b   Mizuno, Takashi ^a   Chun, Yun Shin ^a   Conrad, Claudius ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Colorectal liver metastases; Postoperative hepatic insufficiency; Preoperative chemotherapy; Total liver volume

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER ATROPHY; LIVER FAILURE; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; ATROPHY; COLORECTAL TUMOR; LIVER; LIVER RESECTION; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SECONDARY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATROPHY; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HEPATIC INSUFFICIENCY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85015801747     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.031     Document Type: Article

References (41)

1. Kopetz, S., Chang, G.J., Overman, M.J., Eng, C., Sargent, D.J., Larson, D.W., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
2. Cescon, M., Vetrone, G., Grazi, G.L., Ramacciato, G., Ercolani, G., Ravaioli, M., et al. Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 249 (2009), 995–1002.
3. Zorzi, D., Laurent, A., Pawlik, T.M., Lauwers, G.Y., Vauthey, J.N., Abdalla, E.K., Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94 (2007), 274–286.
4. Lodewick, T.M., de Jong, M.C., van Dam, R.M., Bemelmans, M.H., Neumann, U.P., Olde Damink, S.W., et al. Effects of postoperative morbidity on long-term outcome following surgery for colorectal liver metastases. World J Surg 39 (2015), 478–486.
5. Kishi, Y., Zorzi, D., Contreras, C.M., Maru, D.M., Kopetz, S., Ribero, D., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17 (2010), 2870–2876.
6. Shindoh, J., Tzeng, C.D., Aloia, T.A., Curley, S.A., Zimmitti, G., Wei, S.H., et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 20 (2013), 2493–2500.
7. Vauthey, J.N., Pawlik, T.M., Ribero, D., Wu, T.T., Zorzi, D., Hoff, P.M., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006), 2065–2072.
8. Overman, M.J., Maru, D.M., Charnsangavej, C., Loyer, E.M., Wang, H., Pathak, P., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28 (2010), 2549–2555.
9. Cauchy, F., Aussilhou, B., Dokmak, S., Fuks, D., Gaujoux, S., Farges, O., et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 256 (2012), 746–752 [Discussion 752–744].
10. de Baere, T., Teriitehau, C., Deschamps, F., Catherine, L., Rao, P., Hakime, A., et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 17 (2010), 2081–2089.
11. Simoneau, E., Alanazi, R., Alshenaifi, J., Molla, N., Aljiffry, M., Medkhali, A., et al. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. J Surg Oncol 113 (2016), 449–455.
12. Robinson, S.M., Mann, J., Vasilaki, A., Mathers, J., Burt, A.D., Oakley, F., et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 59 (2013), 318–326.
13. Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003), 518–526.
14. Soubrane, O., Brouquet, A., Zalinski, S., Terris, B., Brezault, C., Mallet, V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251 (2010), 454–460.
15. Miura, K., Nakano, H., Sakurai, J., Kobayashi, S., Koizumi, S., Arai, T., et al. Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol 16 (2011), 257–263.
16. Pawlik, T.M., Scoggins, C.R., Zorzi, D., Abdalla, E.K., Andres, A., Eng, C., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005), 715–722.
17. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
18. Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995), 696–699.
19. Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A.D., Brezault, C., Le Charpentier, M., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004), 460–466.
20. Vauthey, J.N., Chaoui, A., Do, K.A., Bilimoria, M.M., Fenstermacher, M.J., Charnsangavej, C., et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 127 (2000), 512–519.
21. Vauthey, J.N., Abdalla, E.K., Doherty, D.A., Gertsch, P., Fenstermacher, M.J., Loyer, E.M., et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 8 (2002), 233–240.
22. Truant, S., Oberlin, O., Sergent, G., Lebuffe, G., Gambiez, L., Ernst, O., et al. Remnant liver volume to body weight ratio > or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg 204 (2007), 22–33.
23. Imamura, H., Shimada, R., Kubota, M., Matsuyama, Y., Nakayama, A., Miyagawa, S., et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 29 (1999), 1099–1105.
24. Sandrasegaran, K., Kwo, P.W., DiGirolamo, D., Stockberger, S.M. Jr., Cummings, O.W., Kopecky, K.K., Measurement of liver volume using spiral CT and the curved line and cubic spline algorithms: reproducibility and interobserver variation. Abdom Imaging 24 (1999), 61–65.
25. Kishi, Y., Abdalla, E.K., Chun, Y.S., Zorzi, D., Madoff, D.C., Wallace, M.J., et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 250 (2009), 540–548.
26. Brouquet, A., Overman, M.J., Kopetz, S., Maru, D.M., Loyer, E.M., Andreou, A., et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117 (2011), 4484–4492.
27. Passot, G., Chun, Y.S., Kopetz, S.E., Overman, M.J., Conrad, C., Aloia, T.A., et al. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol, 2016.
28. Dindo, D., Demartines, N., Clavien, P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240 (2004), 205–213.
29. Skrzypczyk, C., Truant, S., Duhamel, A., Langlois, C., Boleslawski, E., Koriche, D., et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg 260 (2014), 865–870 [Discussion 870].
30. Mullen, J.T., Ribero, D., Reddy, S.K., Donadon, M., Zorzi, D., Gautam, S., et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204 (2007), 854–862 [Discussion 862–854].
31. Kubota, K., Makuuchi, M., Kusaka, K., Kobayashi, T., Miki, K., Hasegawa, K., et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26 (1997), 1176–1181.
32. Ratti, F., Cipriani, F., Catena, M., Paganelli, M., Aldrighetti, L., Liver failure in patients treated with chemotherapy for colorectal liver metastases: Role of chronic disease scores in patients undergoing major liver surgery. A case-matched analysis. Eur J Surg Oncol 40 (2014), 1550–1556.
33. Narita, M., Oussoultzoglou, E., Bachellier, P., Jaeck, D., Uemoto, S., Post-hepatectomy liver failure in patients with colorectal liver metastases. Surg Today 45 (2015), 1218–1226.
34. Pawlik, T.M., Olino, K., Gleisner, A.L., Torbenson, M., Schulick, R., Choti, M.A., Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11 (2007), 860–868.
35. Makowiec, F., Mohrle, S., Neeff, H., Drognitz, O., Illerhaus, G., Opitz, O.G., et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg 15 (2011), 153–164.
36. King, P.D., Perry, M.C., Hepatotoxicity of chemotherapy. Oncologist 6 (2001), 162–176.
37. Karoui, M., Penna, C., Amin-Hashem, M., Mitry, E., Benoist, S., Franc, B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006), 1–7.
38. Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M.B., Eng, C., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110 (2007), 2761–2767.
39. Rubbia-Brandt, L., Lauwers, G.Y., Wang, H., Majno, P.E., Tanabe, K., Zhu, A.X., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56 (2010), 430–439.
40. Agostini, J., Benoist, S., Seman, M., Julie, C., Imbeaud, S., Letourneur, F., et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 56 (2012), 869–876.
41. Shindoh, J., Truty, M.J., Aloia, T.A., Curley, S.A., Zimmitti, G., Huang, S.Y., et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 216 (2013), 201–209.